In this book, advances in drug therapy for COPD have been highlighted and, after a review of current management, the new developments in long-acting bronchodilators and combinations are reviewed.
It is now recognized that there is a marked heterogeneity among COPD patients and that different patients will benefit from different therapies. This will become increasingly relevant in the future as it will be important to personalize treatment according to the phenotype of the patients and this may require the development of biomarkers to predict and monitor response. This book therefore brings together some of the new information about drug therapy of COPD and also looks towards future developments in this important area.
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